A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of MEDI5884 in Healthy Volunteers

Trial Profile

A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of MEDI5884 in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs MEDI 5884 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; First in man
  • Sponsors MedImmune
  • Most Recent Events

    • 29 Nov 2017 Planned number of patients changed from 56 to 64.
    • 29 Nov 2017 Planned End Date changed from 21 Feb 2018 to 21 May 2018.
    • 29 Nov 2017 Planned primary completion date changed from 21 Feb 2018 to 21 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top